Also, there is an ongoing randomised, double-blind placebo-controlled trial evaluating the efficacy of ARRY-371797, an inhibitor of the p38α MAPK pathway in symptomatic patients with DCM due to a mutation of the gene encoding the lamin A/C protein [59]. This evidence concerns the gene LMNA and familial dilated cardiomyopathy.